TB-500: Benefits, Risks, Human Evidence and 2026 FDA Status

By Peptide Care Index · Sources checked October 14–15, 2026

TB-500 is a lab-made, seven-amino-acid piece of thymosin beta-4, and its healing benefits are unproven in people. Our October 14 audit found no published human-administration study of this fragment. It is not FDA-approved. A July advisory vote reportedly favored listing, but TB-500 remained absent from the codified 503A compounding list checked October 15, 2026.

A study can be real and still fail to support the claim printed beside it. Much of the research cited for TB-500 tested a longer molecule, a different route, or rats. Below, each popular claim sits next to what was actually tested. After that comes where TB-500 legally stands, what its forms and prices mean, and what to ask before you pay anyone.

TB-500 at a glance

• 7 vs. 43 amino acids. TB-500 is the acetylated 17–23 fragment of thymosin beta-4, written Ac-LKKTETQ. The full protein has 43 amino acids. FDA TB-500 briefing · Esposito et al., 2012

• 0 eligible human reports found in our search. Our October 14, 2026 screen of 38 PubMed records found no published study that gave Ac-LKKTETQ to people. Our TB-500 human-study audit

• A positive new result is in rats. A 2026 study found stronger repaired Achilles tendons after about four weeks in rats given material the authors called TB-500. The paper does not state the exact sequence. Biçer et al., 2026

• FDA status:

  • Not an ingredient in any FDA-approved drug.
  • FDA's own staff recommended against adding it to the compounding list.
  • An advisory panel then reportedly recommended for it. Reported vote
  • It was not on the list in the federal code updated through October 13, 2026.

  FDA briefing · 21 CFR 216.23

• Banned in sport at all times under the World Anti-Doping Agency's 2026 list, section S2.3. WADA 2026 Prohibited List

TB-500 benefits: what does the evidence actually show?

The defined TB-500 fragment's injury-recovery benefits are not established in people. Some animal and lab findings are encouraging, one lab test was not, and the related human studies below tested full-length or recombinant thymosin beta-4 instead. Each finding can only tell you about the substance tested, how it was given, and what was measured.

The table pairs each claim you are likely to see with the study behind it. The last column is the question that study leaves open.

TB-500 claims vs. the evidence

Table: Selected evidence reviewed October 15, 2026; the PubMed screening count remains the October 14 audit finding. "Contradicted" means the cited record conflicts with the specific claim. "Unresolved" means the available evidence does not settle that claim; it does not mean there is no evidence at all. "Not applicable" means the cited study or record is not evidence for the particular human-fragment claim. These are requirement-level findings, not safety badges. This table does not identify what is in any product for sale.

What the table adds up to

The evidence supports research interest, not a proven shortcut to recovery. The 2026 rat study is a real positive finding, and it belongs on this page. It still leaves a long way to go. Rats are not people. The material's exact sequence isn't stated. The tendons were surgically repaired, and treatment ran 30 days — described as four weeks in the abstract.

The 2024 lab result cuts the other way. In that test, TB-500 itself did not speed scratch-wound closure. That doesn't prove TB-500 can't help a person. One lab test can't settle that any more than one rat study can.

The related human trials in our ledger are real trials, but they tested full-length or recombinant thymosin beta-4 products as eye drops, skin gel or an IV. Several missed their main goals. Borrowing those results for a TB-500 injection changes the molecule, the route and the condition all at once.

What changes your next step

• You have an offer in front of you. You need the exact substance, the pharmacy and the terms. The table shows why a citation alone won't settle it.
• You have an injury. The first question is the diagnosis and what outcome you're trying to change. That is a separate job from judging a peptide.
• You're a tested athlete. The sport rule comes first. TB-500 is prohibited at all times.
• You're curious. You can stop here. Nothing on this page assumes you should buy anything.

What is TB-500, and is it the same as thymosin beta-4?

TB-500 is a short synthetic peptide, not the whole thymosin beta-4 protein. It copies seven amino acids — positions 17 to 23 — of thymosin beta-4, a 43-amino-acid protein found in most of your cells, and adds a small chemical cap at the front. Research results belong to the substance that was actually studied, so that difference matters.

A few terms, once:

• An amino acid is a building block.
• A peptide is a short chain of amino acids.
• A protein is a longer chain that folds into a working shape.
• A fragment is a piece cut from a longer chain.

TB-500's seven building blocks are written L-K-K-T-E-T-Q. The "Ac-" in front of Ac-LKKTETQ marks an acetyl group, a small chemical cap on the first amino acid.

The identity came from a drug-testing lab. In 2012, scientists analyzing a product sold as "TB-500" found this capped fragment inside it. That paper identified a substance. It did not treat anyone. Esposito et al., 2012 FDA's 2026 review uses the same definition. FDA briefing

"Your body makes it" describes thymosin beta-4. It does not establish the identity, benefit or safety of a synthetic seven-amino-acid fragment sold in a vial.

Names you'll see, and what they actually are

Table: Sources checked October 14, 2026. Some websites use "TB-500" for the full protein. A product's name does not prove what is in the vial.

What do "Ac-," "free base" and "acetate" mean?

These look similar but mean different things. "Ac-" describes the acetyl cap built into the TB-500 molecule. "Acetate" names a salt form — the peptide paired with acetate counterions. That name alone does not establish stability.

FDA treats TB-500 free base and TB-500 acetate as two different active ingredients. FDA briefing A label that just says "TB-500" doesn't tell you which one you have. You can't tell from a vial size or a photo either. If you're comparing an offer, ask for the written chemical identity.

Why do people connect TB-500 with tissue repair?

The interest comes from thymosin beta-4 biology. The seven-amino-acid stretch sits in the part of the protein that binds actin, a protein cells use to hold their shape and move. Lab and animal research has linked short sequences containing this stretch to cell movement, angiogenesis (new blood-vessel growth) and wound repair. Sosne et al., 2010 review

That is a reasonable reason to study TB-500. It doesn't tell you how much, if at all, it helps an injured person. FDA's own review notes it is still not known whether actin binding explains the fragment's reported effects. FDA briefing A believable mechanism is where research starts, not a result.

Why is it called TB-500?

The checked records use TB-500 as a product name; they do not explain the origin of the number 500. FDA's briefing notes that a veterinary TB-500 preparation appeared in 2011 and was marketed to boost performance in horse and greyhound racing. FDA briefing, citing Ho et al., 2012 The number in that name does not specify the amount in a vial.

Is TB-500 FDA-approved or legal in 2026?

TB-500 is not FDA-approved, and the codified 503A bulks list checked October 15, 2026, contains no TB-500 entry. FDA's staff recommended against adding it. An advisory panel reportedly voted to recommend adding it, but that vote is advice, not a final agency decision. The checked records do not establish whether a particular clinic can lawfully supply it.

Three terms explain the whole story:

• Compounding means combining, mixing or altering ingredients to make a medicine for a patient's needs. Section 503A generally uses patient-specific prescriptions; section 503B has a separate framework. FDA says compounded drugs are not FDA-approved, so FDA does not review their safety or effectiveness before sale. FDA: Compounding and the FDA
• The 503A bulks list (21 CFR 216.23) is one statutory basis for using a raw ingredient in 503A compounding, subject to the other applicable conditions. It matters for ingredients that are neither in an approved drug nor covered by an official quality standard called a USP or NF monograph. FDA: Bulk drug substances under 503A
• An advisory committee is a panel of outside experts. It gives FDA non-binding recommendations. FDA meeting page

If the next step for you is understanding whether an advertised TB-500 route holds up, Peptide Care Index's Find My Peptide Path tool has a TB-500 access summary built from the same records. It lists six requirements, each marked with its source, its check date and the question still open, plus questions you can copy for a clinic or pharmacy. It's free to use, with no account or email.

Find My Peptide Path

TB-500 status check: six requirements

Table: Each finding applies only to the requirement in its row, not to TB-500 as a whole. Findings use the same labels as our methodology.

What did the July 2026 panel vote change — and not change?

The reported vote added advice for FDA; it did not itself authorize TB-500 compounding. Adding TB-500 to the codified 503A list requires a final rule to take effect. Even then, being on a compounding list is not the same as FDA approval.

Here is what happened, in order:

1. FDA's scientific staff reviewed TB-500 for one use: wound healing. The nomination they evaluated proposed a 3 mg/mL powder for injection under the skin or into muscle. Staff recommended against listing it. FDA briefing
2. The advisory panel discussed it on July 23, 2026. FDA meeting page
3. The panel voted 8 in favor, 6 against, with 1 abstention, to recommend adding TB-500. This is according to Reuters reporting carried by WMBD, PharmExec and a McDermott Will & Schulte client alert. No minutes or vote record appeared in the FDA meeting materials we accessed on October 15, 2026. We could not independently confirm the tally from the linked webcast.
4. The panel recommended six of the seven peptides it reviewed over the two days: TB-500, BPC-157, KPV, MOTS-c, Epitalon and Semax. It did not recommend emideltide (DSIP), according to the same coverage.
5. We did not identify a final rule adding TB-500. The codified 503A list, checked October 15 and displayed current through October 13, 2026, still had no TB-500 entry. Targeted FDA and Federal Register searches did not establish a later listing action. 21 CFR 216.23

Two details matter more than the headline.

First, the use under evaluation was wound healing. The meeting was not evidence that TB-500 works for tendon repair, muscle recovery, hair or anti-aging. FDA also notes that the use evaluated does not necessarily restrict an eventual listing to that use; any final rule would need to be read on its own terms. FDA briefing, p.7, footnote 1

Second, reporting on the broader peptide discussions shows different concerns among panel members. PharmExec describes support for leaving decisions with patients, doctors and pharmacists, and concern that permission to compound could be mistaken for proof of effectiveness. Those reported comments do not establish each member's reason for the TB-500 vote. PharmExec

Off-label use is a different category. It means using an FDA-approved drug in a way its approved label does not describe. Calling an unapproved TB-500 product "off-label" does not make it an approved finished medicine, and compounded products are not FDA-approved. FDA: off-label use

For the full July agenda, including the uses FDA reviewed for each peptide, see our FDA peptide hearing tracker. For list-by-list status, see the FDA peptide compounding list.

TB-500's paper trail

Table: Dates are when events happened, not when we checked them. All sources checked October 14–15, 2026.

Can a U.S. doctor prescribe TB-500, or a pharmacy compound it?

The records checked do not establish a supported U.S. supply route for a particular TB-500 offer. FDA's evaluation found no approved-drug ingredient or applicable monograph, and the current codified 503A list does not name it. Withdrawal of a nomination does not by itself establish coverage under an interim policy. A clinic offering TB-500 should be able to name the exact substance, the pharmacy that would dispense it, and the specific rule or policy it relies on.

A prescription, a clinic's advertisement, a pharmacy license or a lab certificate doesn't answer that question by itself. Each shows something different. None shows that every requirement for supplying this ingredient has been met.

Our October 14 audit's targeted ClinicalTrials.gov searches did not identify a genuine U.S. trial offering the defined fragment. The TB-500 match, NCT07487363, still described itself as a fictional example when rechecked October 15. This is not an exhaustive search of every substance alias or access program. Only a real study team can confirm recruitment and eligibility.

This is not legal advice, and state rules vary. If you need a legal answer about a specific arrangement, a pharmacy-law attorney is the right person to ask.

What about TB-500 sold "for research use only"?

"Research use only" or "not for human use" is not a patient-treatment authorization. FDA's review found websites selling TB-500 powders in 2, 3, 5, 10 and 15 mg sizes with that label. FDA briefing Those labels do not make a product a prescription-compounded medicine. This page does not recommend research-use goods as a treatment source.

Is TB-500 banned in sports?

Yes. The World Anti-Doping Agency's 2026 list prohibits thymosin beta-4 and its derivatives, including TB-500, in and out of competition, under section S2.3. WADA 2026 Prohibited List

For 2027, thymosin beta-4 and its derivatives, including TB-500, remain specifically listed in S2.3. The broader S0 wording adds "peptides" without human therapeutic approval only when they are not covered by another section. USADA's advisory describes S0 or other classes, not a move of TB-500 into S0. The 2027 list takes effect January 1, 2027. WADA 2027 list, pp.4 and 8 · USADA 2027 advisory

A ban is an anti-doping rule, not proof that TB-500 improves performance. A clinician's prescription does not make it permitted in tested sport. If you compete, check with your sport's governing body.

Has TB-500 been tested in people?

Our targeted audit found no published human-administration report for the defined fragment. Human studies of related thymosin beta-4 products exist, but they tested different molecules. Our October 14, 2026 audit screened 38 PubMed records and found no published report of the defined TB-500 fragment, Ac-LKKTETQ, being given to people.

That audit used a targeted search, not a review of every database in the world. A report could exist under another name, or remain unpublished. The full method, all 38 decisions and downloadable files are on our TB-500 human-study audit.

Here is how the 38 records broke down:

Source: our audit, October 14, 2026.

What can the related human studies tell you?

A human study can tell you about its own product and use without telling you anything about a TB-500 injection. Before borrowing a study's result, check three things: the treatment actually given, the people studied, and whether the trial's main test succeeded.

The dry-eye trial is a good example. It tested RGN-259, a full-length thymosin beta-4 eye drop, in 72 people over 28 days. A trial's primary endpoint is the main result it was designed to test. Secondary endpoints are extra measures. Here, neither primary endpoint was significantly better than placebo, while some secondary measures favored the drops. Sosne and Ousler, 2015

Both results deserve to be reported, side by side. Neither tells you about a seven-amino-acid fragment injected under the skin for a sore tendon. And the full paper's safety section lists adverse events, so "no adverse events" isn't an accurate summary of that trial either. An event during a study is not automatically caused by the treatment. Full report, Results

Two more examples show the same pattern:

• An IV safety study. Forty healthy volunteers were assigned to intravenous synthetic thymosin beta-4 or placebo. The study reported no serious adverse events. That's a safety observation for that molecule, route and short study period — not for TB-500. Ruff et al., 2010
• A heart study. Ninety-six heart-attack patients received recombinant thymosin beta-4 or placebo. The overall result was not significant; a subgroup treated early looked better. A subgroup result is not overall success. Zhang et al., 2025

Our audit maps eight related human reports — eye, skin-ulcer, heart and safety studies — by molecule, route and result, in one table. See the related-study ledger

Does "human research" always mean people received it?

No. Researchers can work with human blood, serum or liver cells in a lab without giving a substance to anyone. That work is called in vitro, meaning outside a living body.

For example, WADA funded a project on how TB-500 breaks down, using human liver preparations and blood samples in the lab. It is useful for drug testing. It is not a treatment study. WADA research project

Registry listings need a close read too. The TB-500 match in our October 14 targeted registry search, NCT07487363, lists a sponsor (Hudson Biotech), one site in Shenzhen, China, an estimated 80 participants, a March 23, 2026 update and a "recruiting" status. Its own summary calls it a fictional example, and it has no results. Complete NCT07487363 record, rechecked October 15 A status field doesn't outweigh the record's own description, and the record offers no U.S. route to treatment.

Does TB-500 help tendon, muscle or joint injuries?

The checked evidence does not establish that the defined TB-500 fragment repairs human tendons, muscles or joints. A 2026 study is genuinely positive for material labelled TB-500 in rats, though its exact sequence is unresolved. It is not a forecast for a person.

Here is what the rat study did and found. Biçer et al., 2026, full report

• Setup. Researchers cut and surgically repaired the Achilles tendon in 32 male rats. They split the rats into four groups of eight: vehicle control, BPC-157, TB-500, and both. The treatments were given by daily injections into the belly cavity for 30 days; controls received vehicle. Four tendons per group were used for mechanical testing and four for tissue assessment.
• Strength. The TB-500 group's tendons held more load before breaking than the control group's, a statistically significant difference.
• Tissue. The TB-500 group also scored better on two microscope-based tissue scores.
• Combination. No additional benefit from giving both peptides was detected over either alone.

That's worth knowing. Here is why it still can't tell you what TB-500 would do for your tendon:

• Species. Rat tendons heal on a different scale and timeline than human ones.
• Substance. The paper calls the material "synthetic thymosin beta-4 (TB-500)." It doesn't give the sequence, so it isn't certain it matches the Ac-LKKTETQ fragment.
• Situation. Every tendon had been surgically repaired. The peptide was added to surgery, not used instead of it.
• Time. About four weeks shows early healing, not long-term strength or re-injury risk.
• Route. Injection into the belly cavity does not test injection under the skin or into muscle.

The authors themselves call it exploratory. A positive rat study is the kind of result that justifies a human trial. It doesn't replace one.

Why does "less pain" not prove that a tendon healed?

Feeling better and tissue repairing are different results, and a study has to measure the one it claims. In the BPC-157 and "TB4" knee report, four of the 16 people reached by phone had received the combination. Three of those four reported improvement. No objective follow-up checked tissue repair, and there was no placebo or untreated control group. Lee and Padgett, 2021

Their improvement may be real. But injuries often get better with time, rest and rehab. Without a randomized control, the report cannot tell how much any peptide added — or which of the two did it. Online stories have the same limit, plus one more: nobody can confirm what was in the vial.

Questions worth settling before you consider any peptide for an injury

The most useful step is often a clearer diagnosis, not a different product. These questions apply whatever you decide:

1. What exactly is injured, and how was that confirmed?
2. What outcome are you trying to change — pain, strength, range of motion, return to a sport?
3. How will you know whether it changed, and by when?
4. What treatments with tested evidence exist for this injury, and have you tried them?
5. What's the plan if things don't improve?

A sports-medicine doctor or physical therapist can help with all five. This page doesn't replace that care.

What are TB-500's side effects and safety risks?

The checked evidence cannot supply reliable human side-effect rates for the defined TB-500 fragment. FDA's 2026 evaluation did not identify human-administration data or nonclinical toxicity and carcinogenicity studies. It raised concerns that injected forms could trigger immune reactions or carry impurities. "Unknown" is the honest answer, and it is not the same as "safe."

What FDA's 2026 review found: FDA briefing · FDA safety-risk table

• No human exposure data identified in FDA's evaluation for drug products containing the fragment. FDA says it lacks important information about potential harm. This is a finding from its review, not proof that nobody has used a product carrying the name.
• No FAERS reports retrieved through March 26, 2025, using FDA's stated search terms, and no adverse-event cases identified in its literature review. This is not an October 2026 database count. FDA briefing, pp.30–31
• Two complaint reports from January 1, 2004, through March 10, 2025, in FDA's Human Foods Complaint System mentioned "blended TB-500 and BPC-157." Neither included a safety assessment. FDA briefing, p.31
• Immune reaction risk. Injected peptides can provoke immunogenicity — the immune system reacting to the peptide. FDA points to clumping (aggregation) and manufacturing impurities as possible causes.
• Impurity risk. Making peptides in a lab can leave behind shortened or altered chains.
• No nonclinical toxicity or carcinogenicity studies of either TB-500 form were identified at the time of that FDA evaluation. FDA briefing, pp.28–29

"No reports" is not proof of safety. A spontaneous-report search does not tell us how many people used a product, whether every reaction was reported, or how often a reaction occurs.

The side effects listed on many websites — headache, tiredness, nausea, redness where it was injected — don't come from controlled TB-500 studies. They may be real for some people. Nobody knows how often they happen, or whether the peptide, an impurity, or the injection itself caused them. For a cross-peptide view, see our peptide side-effects chart and adverse-event reports.

Does TB-500 cause cancer?

The evidence doesn't establish a human cancer-risk estimate either way. FDA identified no nonclinical carcinogenicity studies of either TB-500 form in its 2026 evaluation; that gap supports neither "it causes cancer" nor "it can't cause cancer." FDA briefing, p.29 A concern drawn from full-length thymosin beta-4 or blood-vessel-growth research cannot simply be transferred to the fragment.

What's known is the gap: the checked sources do not establish long-term safety for the defined fragment in people.

Who has more unanswered questions?

Some people have more to lose from an unknown. That includes people who are pregnant or breastfeeding, children and teens, people with a history of cancer, people with immune conditions, and anyone taking other medicines. This isn't a proven list of reasons to avoid TB-500 — that evidence doesn't exist. It's a list of questions this page cannot clear and a clinician should discuss. A consultation does not fill the missing safety evidence.

What should you do after a worrying reaction?

New symptoms after using an unverified product need medical attention, not a new online protocol. This is general emergency guidance, not a measured TB-500 risk. MedlinePlus: anaphylaxis · MedlinePlus: cellulitis

• Call 911 right away for trouble breathing, swelling of the face, tongue or throat, fainting, or collapse.
• Get prompt care for an injection site that becomes hot, red, swollen and painful and is spreading, especially with fever.
• For anything else that worries you, contact a doctor or pharmacist. Bring the packaging, any label or certificate, and when and how you used it.

Is there a proven TB-500 dose, cycle or timeline?

No validated injury-recovery regimen was identified for the defined fragment. Our dated audit found no eligible published human-administration report from which to establish a dose, schedule, cycle or healing timeline. An online loading or maintenance schedule is not trial-based merely because it is detailed. Audit method

Here's what the records actually contain:

• The nomination FDA reviewed proposed a 3 mg/mL powder for injection. That is the proposed prepared-product concentration, not a dose, amount per vial or schedule. A dry powder does not itself have a liquid volume. FDA briefing
• Animal studies used their own amounts, routes and timeframes. Converting a rat or horse amount into a human dose isn't a reliable method, and we don't do it.
• Thymosin beta-4 trials used different molecules, given as eye drops, skin gel or an IV. Their amounts don't carry over.

People also ask about TB-500's half-life — how long it lasts in the body. These four things are easy to mix up but measure different questions:

• how fast a substance enters the blood,
• how fast it leaves the blood,
• how long a drug test can detect its breakdown products,
• whether a patient gets better.

FDA's discussion of how TB-500 moves through the body comes from animal work, including horses. None of it supports a personal schedule.

We don't give doses, conversions, mixing (reconstitution) steps or injection instructions. If anyone gives you a TB-500 dose, ask one question: Which study in people is this number from?

Capsules, injections, nasal sprays and blends: does the form change anything?

Changing the form doesn't fill the evidence gap. FDA's July 2026 evaluation concerned a powder proposed for injection under the skin or into muscle. Our October 14 targeted audit identified no published administration report of the defined fragment by any route. Capsules, sprays and blends add another question: whether the product contains the fragment at all, and whether it reaches the place it's meant to work.

You may see TB-500 sold as capsules counted in micrograms, as nasal sprays, or premixed with BPC-157. Here's what each form would need before a claim could transfer to it.

Table: An evidence-matching guide, not a catalog of approved or verified products. Sources: FDA briefing, our human-study audit. Checked October 14, 2026.

For the parallel question about BPC-157 pills, see what BPC-157 capsule evidence shows.

Is TB-500 better than BPC-157 — or better together?

The checked human evidence does not establish a winner or an added benefit from combining them. The popular rule "BPC-157 for local repair, TB-500 for whole-body repair" is a theory, not a tested way to choose. In the 2026 rat study, no added benefit from combining the two was detected. The human combination report discussed here had four combination recipients and no randomized or placebo control.

Sources: FDA July 2026 meeting page, 21 CFR 216.23, Biçer et al., 2026, checked October 14–15, 2026. For BPC-157's own status, see is BPC-157 FDA-approved?. To compare more peptides, use our peptide comparison chart.

What does TB-500 cost?

There's no honest single price for TB-500. Listings sell different amounts in different packages, and no tested schedule exists to turn a vial into a month. A price also doesn't prove a legal supply route.

Two TB-500 listings in our dated peptide price list, rechecked on the providers' own pages October 15, 2026, show the problem. Both sites market patient care, not research-use-only supplies; that is their positioning, not our verification of a lawful dispensing route:

• One listing: a 5 mL vial labeled 10 mg/mL — 50 mg in total — for $80 per vial, plus a $39 review and $15 shipping. The vial amount is our calculation: 5 mL × 10 mg/mL = 50 mg. For one vial in one order, the known published charges are $134: $80 + $39 + $15, our calculation. The review is due first; pharmacy charges follow separately if prescribed and filled. This is not a monthly price or a verified complete care bill. Rx Peps Direct product page · published pricing
• Another listing: 5 mg as listed, for $200, under a seller-defined "4-week supply" heading. The full package contents, any required new-patient visit or labs, and delivery and follow-up charges were not established. Payment is arranged by the clinic after a request. EDGE Integrative Wellness's published list

These aren't comparable products. One price is per vial plus known order fees. The other is for a seller-defined "supply." Neither price establishes the exact molecular identity, whether the supplied batch matches its testing, the dispensing pharmacy's applicable authority, or a validated treatment duration. A "four-week supply" is the seller's label, not a regimen established by our human-fragment evidence search.

Read the cancellation terms before paying for the review. Rx Peps Direct states no membership and optional automatic refills, each with another $39 review. Its review fee becomes nonrefundable once review begins, even if the prescription is denied; a request before review starts is subject to approval. Medication refunds are the pharmacy's separate responsibility. This audit did not establish any additional mandatory labs, ongoing follow-up charges or pharmacy refund terms. Published terms · review-fee refund policy

EDGE's list does not establish a complete first bill, minimum commitment, automatic-renewal rules or refund terms if no prescription or supply results. Those details remain unknown, not free. Neither offer was purchased, and no state eligibility, pharmacy license or batch certificate was independently verified.

A listed price is one line on a receipt, not the full bill. A real total for a clinic offer can include:

• consultation
• the product (strength and quantity)
• required lab tests
• membership or program fees
• shipping, including cold shipping
• follow-up visits
• first-period versus renewal charges
• cancellation terms
• what you'd get back if nothing is prescribed or filled

A charge that isn't disclosed is unknown, not $0.

Example: reading a TB-500 offer

This is a hypothetical example — not a real offer, and not a market price.

Our arithmetic: $150 + $200 = $350. That's not a monthly cost. We didn't assume a quantity, schedule or length of treatment. In this example, the $150 consultation is the money at risk if nothing is prescribed. Real terms have to be read, not assumed.

A missing written answer is a reason to wait, not to switch to a different seller's claim. Sometimes the useful decision is not paying until the question is answered.

What to check before you pay for TB-500

Find out exactly what is being sold, and who is responsible for it. "TB-500" on a label doesn't tell you the sequence, salt form, amount, sterility or legal basis for supplying it. A purity certificate answers only part of that.

What a TB-500 label can mean

Table: Based on FDA's TB-500 briefing and July 23, 2026 presentations, checked October 14, 2026. We have not tested any product.

Questions to send before you pay

Copy these into an email or bring them to an appointment. They work with any clinic or pharmacy, including one you already know.

1. What is the exact peptide — the 7-amino-acid TB-500 fragment or full-length thymosin beta-4? Which chemical form (free base or acetate), strength and route?
2. Which study in people supports this use of this product, and what outcome did it measure?
3. Who would prescribe it, and are they licensed where I live? Which pharmacy would dispense it, and can it ship to my state?
4. What specific rule or policy are you relying on to supply this ingredient?
5. Which batch does your testing cover? Did it test identity, sterility and endotoxins? What wasn't tested?
6. What do I pay today? What's charged later, and under what conditions?
7. Are the consultation, product, labs, membership, shipping and follow-up charged separately? What renews automatically, and how do I cancel?
8. Is there a minimum commitment? What's refunded if nothing is prescribed or the pharmacy can't fill it?
9. If I compete in a tested sport: do you understand TB-500 is prohibited at all times under anti-doping rules?

Copy questionsPrint questions and examples

These are questions, not a pass/fail result for any offer. A clinic that can't answer them in writing has told you something useful.

If you're holding an offer and want these checks in one place, Peptide Care Index's Find My Peptide Path walks through the provider check — who prescribes, who dispenses, which states — and the fee checklist that shows which charges are still missing. It also gives you a short set of questions to copy or print for a clinic or your own doctor. It's an information guide, not a medical evaluation, and it won't recommend a peptide or promise a prescription.

Find My Peptide Path

TB-500 in horse racing

Early published TB-500 records concern racing and drug detection, not human injury treatment. FDA's review notes a veterinary TB-500 preparation was marketed from 2011 to boost performance in horse and greyhound racing. FDA briefing Testing labs then built methods to detect TB-500 and its breakdown products in horse urine and blood. Ho et al., 2012

FDA's briefing also describes a study that tracked how TB-500 moved through the bodies of Thoroughbred horses after injection. That study measured levels in the blood. It did not test healing.

A horse-product review is not a controlled healing study — in horses or in people.

How we checked this page

We read the primary records and kept each finding tied to the molecule, route and result it actually concerns. This is an editorial source review. It is not product testing, clinical assessment or a legal opinion about any specific purchase.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

What we actually checked

• Editorial source review: the linked FDA briefing and presentation sections, current meeting materials, safety-risk and 503A pages, and 21 CFR 216.23 were inspected on October 15, 2026. The code displayed an October 13 currency date. Targeted FDA and Federal Register searches did not identify a later approval or final TB-500 listing rule; this was not a review of every possible transaction or state rule.
• Study reading: full text of the dry-eye trial, knee report and 2026 rat study; original abstracts for the other cited study findings; and relevant full-text NL005 identity/methods passages. The Sosne 2010 mechanism paper is a review, not a new experiment. FDA's interpretation of the non-acetylated mouse material was checked on printed page 26.
• Dated search, not a new 38-record screen: we checked our October 14 human-study audit and its method. Its count and classifications remain that audit's findings; we did not rerun every screening decision here. The complete NCT07487363 API record was rechecked and still described itself as fictional.
• Sport: WADA's 2026 and 2027 list text and relevant PDF pages, plus USADA's 2027 advisory. TB-500 remains named in S2.3 in both lists.
• The panel vote: retained as an attributed report from Reuters, PharmExec and McDermott. No official tally or minutes appeared in the FDA materials accessed, and the linked webcast could not be independently checked.
• Prices and the path: the two providers' public offers, Rx Peps Direct's pricing, terms and refund policy, and our public path content. These were source checks, not purchases, checkout completion or independent pharmacy/batch verification. The path is publicly readable and advertises free use without an account or email; interactive copy/print/highlight testing did not complete in our browser session.
• What we did not do: buy or test a product, contact a clinic or pharmacy, verify a license or state coverage, or obtain clinician, pharmacist or regulatory-attorney review of this page. This source-review and production audit used AI assistance under our editorial standards.

Read more about how we compare, our editorial standards, how the site works and how we make money. Spot an error or a newer source? Send a correction.

Other questions about TB-500

Who should use TB-500?

The checked evidence does not establish a group of people who benefits from the defined TB-500 fragment. Anyone subject to anti-doping rules should not use it. For an injury, ask a clinician about treatments with tested evidence — FDA's staff noted that approved wound treatments already exist.

Is TB-500 a steroid or a hormone?

TB-500 is a short peptide — a chain of seven amino acids — not a steroid, and the checked sources do not establish it as a hormone-replacement treatment. Some hormones are peptides, so "peptide" alone does not answer the hormone question. Its chemical category says nothing about whether it's safe or effective. FDA substance description

Can a drug test detect TB-500?

Anti-doping labs have published methods to detect TB-500 and its breakdown products, and it is on WADA's prohibited list. Whether a particular test looks for it depends on that program's panel. Ask the testing program what it covers. The published detection work is not a personal clearance or detection-window guarantee. Original detection research · WADA laboratory project

Is "TB-500" ever sold as full-length thymosin beta-4?

Some websites use the names as if they meant the same thing, so a label alone can't tell you. Ask for the sequence and the number of amino acids in writing.

Your next step

You don't need to choose a peptide to make progress. You can name the claim that's still unproven, the product detail that's missing, or the charge nobody has explained.

• If you were curious, you have the answer: interesting animal results, no eligible human-fragment report in our dated search, not FDA-approved, and absent from the checked codified 503A list.
• If you're injured, settle the diagnosis and discuss a treatment plan with tested evidence before judging a vial.
• If you compete in a tested sport, the anti-doping rule settles it.
• If you're holding an offer, the questions above show what still needs a written answer.

Before you commit money, put the unanswered questions in one place. Find My Peptide Path shows the TB-500 access summary, walks through the provider and fee checks, and gives you questions to copy for a clinic or pharmacy you already know. Free, no account or email.

Find My Peptide Path

Sources

Sources were inspected during preparation and the October 15, 2026 audit at the reading depth described above. The 38-record screen remains dated October 14. Study years, database cutoffs and rule effective dates are not source-check dates.

1. U.S. Food and Drug Administration. FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate). July 23–24, 2026 Pharmacy Compounding Advisory Committee; staff evaluation dated May 15, 2026. Staff analysis, not a final agency decision.

2. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Agenda, uses evaluated, posted materials. No minutes or vote record appeared in the materials accessed October 15; linked webcast verification was unavailable.

3. U.S. Food and Drug Administration. July 23, 2026 Meeting — FDA Presentations. Quality and identity sections.

4. Electronic Code of Federal Regulations. 21 CFR 216.23 — Bulk drug substances for 503A compounding. Shown as up to date through October 13, 2026.

5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. "Nominated but withdrawn" table, TB-500 fragment row.

6. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A.

7. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.

8. Reuters, via WMBD. FDA advisory panel votes to place popular peptide TB-500 on compounding list. July 23, 2026.

9. PharmExec. FDA Panel Votes to Loosen Restrictions for Four Peptides.

10. McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.

11. World Anti-Doping Agency. 2026 Prohibited List, section S2.3.

12. U.S. Anti-Doping Agency. Athlete Advisory: What's New on the 2027 WADA Prohibited List? Published October 6, 2026.

13. World Anti-Doping Agency. Investigation of in vitro/ex vivo TB-500 metabolism.

14. Esposito et al. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis, 2012.

15. Ho et al. Doping control analysis of TB-500 … in equine urine and plasma. Journal of Chromatography A, 2012.

16. Sosne et al. Biological activities of thymosin β4 defined by active sites in short peptide sequences. FASEB Journal, 2010. Review.

17. Biçer et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Joint Diseases and Related Surgery, 2026. Full report · PDF. Methods and Figure 2 inspected; mechanical n=4 tendons per group.

18. Rahaman et al. Simultaneous quantification of TB-500 and its metabolites … and their screening by wound healing activities in vitro. Journal of Chromatography B, 2024.

19. Sosne and Ousler. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled trial. Clinical Ophthalmology, 2015. Accessible full text; primary endpoints and adverse-event section inspected.

20. Guarnera et al., 2010. PubMed record: full-length thymosin beta-4 gel for venous ulcers.

21. Ruff et al., 2010. PubMed record: intravenous thymosin beta-4 safety study in healthy volunteers.

22. Wang et al., 2021. Full text: NL005 recombinant thymosin beta-4 healthy-volunteer study. Journal of Cellular and Molecular Medicine.

23. Zhang et al., 2025. PubMed record: recombinant thymosin beta-4 after heart attack. Cardiovascular Research.

24. Lee and Padgett. Intra-articular injection of BPC-157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 2021.

25. ClinicalTrials.gov. NCT07487363 · complete API record. Rechecked October 15, 2026; record describes itself as a fictional example.

26. Peptide Care Index. TB-500 human studies: 0 direct studies found in our audit. Evidence checked October 14, 2026.

27. Peptide Care Index. Peptide price list. Original TB-500 rows dated October 14; direct offer rechecks and extra-fee analysis on this page dated October 15, 2026.

28. World Anti-Doping Agency. 2027 Prohibited List, effective January 1, 2027. Printed pages 4 and 8 inspected: S0 catch-all and explicit TB-500 entry under S2.3.

29. Philp et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 2003. Original abstract and FDA's form-specific analysis read.

30. Rx Peps Direct. TB-500 product price, pricing, terms and refund policy. Provider-published information checked October 15, 2026; not a clinical or regulatory endorsement.

31. EDGE Integrative Wellness. Peptide price list and ordering disclosures. Provider-published information checked October 15, 2026; package and additional-charge limitations described above.

32. MedlinePlus. Anaphylaxis and cellulitis. General urgent-care guidance, not TB-500-specific incidence evidence.

33. U.S. Food and Drug Administration. Understanding unapproved use of approved drugs (off-label use).

34. Federal Register. April 16, 2026 Pharmacy Compounding Advisory Committee meeting notice. A meeting notice, not a rule adding TB-500. Targeted searches for subsequent TB-500 listing actions did not identify a final listing rule during this audit.

35. U.S. Food and Drug Administration. BPC-157 briefing, printed page 9. Staff evaluation dated May 11, 2026; approval/monograph passage checked October 15 for the short BPC-157 comparison.